LEADER 02132oam  2200541   450 
001 9910708186403321
005 20151005134644.0
035   $a(CKB)3460000000108867
035   $a(OCoLC)798496440$z(OCoLC)651946174$z(OCoLC)654126262$z(OCoLC)798566624
035   $a(EXLCZ)993460000000108867
100   $a20120708d1998      ua             0
101 0 $aeng
135   $aurbn||||a||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aFDA oversight $eblood safety and the implications of pool sizes in the manufacture of plasma derivatives : hearing before the Subcommittee on Human Resources of the Committee on Government Reform and Oversight, House of Representatives, One Hundred Fifth Congress, first session, July 31, 1997
210  1$aWashington :$cU.S. Government Printing Office,$d1998.
215   $a1 online resource (iii, 427 pages) $cillustrations
300   $aTitle from title screen (viewed on Oct. 5, 2015).
300   $a"Serial no. 105-70."
320   $aIncludes bibliographical references.
517   $aFDA oversight 
606   $aPlasma products$zUnited States$xSafety measures
606   $aBlood plasma$xSafety measures
606   $aBlood$xCollection and preservation$zUnited States$xSafety measures
606   $aBlood$xCollection and preservation$xSafety measures$2fast
606   $aBlood plasma$xSafety measures$2fast
606   $aPlasma products$xSafety measures$2fast
607   $aUnited States$2fast
608   $aLegislative hearings.$2lcgft
615  0$aPlasma products$xSafety measures.
615  0$aBlood plasma$xSafety measures.
615  0$aBlood$xCollection and preservation$xSafety measures.
615  7$aBlood$xCollection and preservation$xSafety measures.
615  7$aBlood plasma$xSafety measures.
615  7$aPlasma products$xSafety measures.
801  0$bOCLCE
801  1$bOCLCE
801  2$bOCLCO
801  2$bOCLCQ
801  2$bOCLCF
801  2$bOCLCQ
801  2$bGPO
906   $aBOOK
912   $a9910708186403321
996   $aFDA oversight$93525593
997   $aUNINA